Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IPI Legacy Liquidation CoIMPL · Entity 15659 | Director | June 16, 2023 | June 20, 2023 |
| PLIANT THERAPEUTICS, INC.PLRX · Entity 7022 | Director | June 11, 2026 | June 12, 2026 |
| Pyxis Oncology, Inc.PYXS · Entity 5986 | Director | March 24, 2026 | March 25, 2026 |
| Seagen Inc.SGEN · Entity 13956 | EVP, Commercial | November 29, 2018 | November 30, 2018 |
| Xenon Pharmaceuticals Inc.XENE · Entity 2602 | Chief Commercial Officer | January 09, 2026 | January 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IPI Legacy Liquidation Co
Report date June 16, 2023 · Filed June 20, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.34 · Expires 2033-06-15 | Direct | 13,222 |
Reported balance
After 2023-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-16 · Grant · Acquired 13,222 · Balance 13,222 F1: The option is 100% vested on June 16, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The option is 100% vested on June 16, 2024.
PLIANT THERAPEUTICS, INC.
Report date June 11, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.14 · Expires 2036-06-11 | Direct | 70,000 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 70,000 · Balance 70,000 F1: 25% of the shares subject to such option vest and become exercisable on October 1, 2026, January 1, 2027, and April 1, 2027, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 11, 2026 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to such option vest and become exercisable on October 1, 2026, January 1, 2027, and April 1, 2027, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 11, 2026 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting.
Pyxis Oncology, Inc.
Report date March 24, 2026 · Filed March 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.36 · Expires 2036-03-24 | Direct | 45,867 |
Reported balance
After 2026-03-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-24 · Grant · Acquired 45,867 · Balance 45,867 F1: The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date.
Seagen Inc.
Report date November 29, 2018 · Filed November 30, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 72,556 |
Reported balance
After 2018-11-29 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-11-29 · Sale · Disposed 7,000 · Balance 72,556 F1: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $62.8711 to $62.9508. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F2: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $62.8711 to $62.9508. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F2: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.
Xenon Pharmaceuticals Inc.
Report date January 09, 2026 · Filed January 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.15 · Expires 2036-01-08 | Direct | 40,000 |
Reported balance
After 2026-01-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-09 · Grant · Acquired 40,000 · Balance 40,000 F1: Vesting 25% on January 9, 2027, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. |
| Restricted Share UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 20,000 |
Reported balance
After 2026-01-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-09 · Grant · Acquired 20,000 · Balance 20,000 F2: Each restricted share unit represents a contingent right to receive one Common Share vesting 25% on each of the first four anniversaries of the date of grant, beginning on January 9, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Vesting 25% on January 9, 2027, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.
F2: Each restricted share unit represents a contingent right to receive one Common Share vesting 25% on each of the first four anniversaries of the date of grant, beginning on January 9, 2027.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
GW PHARMACEUTICALS PLC
Report date May 05, 2021 · Filed May 07, 2021
Section 16 reporting ended · disclosed 2021-05-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 1
1 source rowRow 1 · 2021-05-05 · Disposition to issuer · Disposed 5,556 · Balance 0 F1: On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement") (continued in footnote 2). F2: At the effective time of the Scheme of Arrangement, Scheme Shareholders (as defined in the Scheme of Arrangement) became entitled to receive for each Scheme Share (as defined in the Scheme of Arrangement) held by them an amount equal to $16.66 2/3 in cash plus 0.010030 ordinary shares, nominal value $0.0001 per share, of Jazz ("Jazz ordinary shares"). The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $15.30 · Expires 2029-05-28 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-05-05 · Disposition to issuer · Disposed 54,192 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-05-05 · Disposition to issuer · Disposed 22,068 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5: These stock options were granted with automatic vesting on exercisable date. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-05-05 · Disposition to issuer · Disposed 98,040 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5: These stock options were granted with automatic vesting on exercisable date. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-05-05 · Disposition to issuer · Disposed 106,320 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5: These stock options were granted with automatic vesting on exercisable date. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-05-05 · Disposition to issuer · Disposed 177,180 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5: These stock options were granted with automatic vesting on exercisable date. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-05-05 · Disposition to issuer · Disposed 46,896 · Balance 0 F4: Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023. F5: These stock options were granted with automatic vesting on exercisable date. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-05-05 · Disposition to issuer · Disposed 75,024 · Balance 0 F4: Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023. F5: These stock options were granted with automatic vesting on exercisable date. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement") (continued in footnote 2).
F2: At the effective time of the Scheme of Arrangement, Scheme Shareholders (as defined in the Scheme of Arrangement) became entitled to receive for each Scheme Share (as defined in the Scheme of Arrangement) held by them an amount equal to $16.66 2/3 in cash plus 0.010030 ordinary shares, nominal value $0.0001 per share, of Jazz ("Jazz ordinary shares"). The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021.
F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration.
F4: Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023.
F5: These stock options were granted with automatic vesting on exercisable date.
STEMLINE THERAPEUTICS INC
Report date June 10, 2020 · Filed June 10, 2020
Section 16 reporting ended · disclosed 2020-06-10. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-06-10 transaction · row 1
1 source rowRow 1 · 2020-06-10 · Other · Disposed 35,468 · Balance 0 F1: Disposed of in connection with a tender offer made pursuant to an agreement and plan of merger among Issuer, Berlin-Chemie AG, and Mercury Merger Sub, Inc., dated as of May 3, 2020, in exchange for $11.50 per share, net to the holder in cash, plus one contractual contingent value right ("CVR") per share. Each CVR represents the right to receive a payment of $1.00 in cash upon the achievement of a certain milestone relating to the first sale of ELZONRIS in any one of certain countries following a marketing authorization approval by the European Commission. The CVR milestone must be achieved on or prior to December 31, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of in connection with a tender offer made pursuant to an agreement and plan of merger among Issuer, Berlin-Chemie AG, and Mercury Merger Sub, Inc., dated as of May 3, 2020, in exchange for $11.50 per share, net to the holder in cash, plus one contractual contingent value right ("CVR") per share. Each CVR represents the right to receive a payment of $1.00 in cash upon the achievement of a certain milestone relating to the first sale of ELZONRIS in any one of certain countries following a marketing authorization approval by the European Commission. The CVR milestone must be achieved on or prior to December 31, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 12, 2026 17:00 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $1.14 | $0.00 |
DisclosureSEC source: 0001746473-26-000099 · wk-form4_1781298048.xml · derivative · entry 1 Cline Darren S · CIK 0001633639 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2036-06-11 F1 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on October 1, 2026, January 1, 2027, and April 1, 2027, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 11, 2026 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting. Read SEC document |
| March 24, 2026 Filed Mar 25, 2026 17:07 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | GrantStock Option (Right to Buy) · Derivative | 45,867 | $0.00 Strike: $1.36 | $0.00 |
DisclosureSEC source: 0001193125-26-124325 · ownership.xml · derivative · entry 1 Cline Darren S · CIK 0001633639 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,867 Underlying: Common Stock · 45,867 shares Expires 2036-03-24 F1 · derivative.exercise_date: The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| January 09, 2026 Filed Jan 9, 2026 23:53 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantRestricted Share Units · Derivative | 20,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-009235 · ownership.xml · derivative · entry 2 Cline Darren S · CIK 0001633639 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 20,000 shares Expires not disclosed F2 · derivative.exercise_date: Each restricted share unit represents a contingent right to receive one Common Share vesting 25% on each of the first four anniversaries of the date of grant, beginning on January 9, 2027. F2 · derivative.expiration_date: Each restricted share unit represents a contingent right to receive one Common Share vesting 25% on each of the first four anniversaries of the date of grant, beginning on January 9, 2027. Read SEC document |
| January 09, 2026 Filed Jan 9, 2026 23:53 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantShare Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $42.15 | $0.00 |
DisclosureSEC source: 0001193125-26-009235 · ownership.xml · derivative · entry 1 Cline Darren S · CIK 0001633639 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Shares · 40,000 shares Expires 2036-01-08 F1 · derivative.exercise_date: Vesting 25% on January 9, 2027, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
| June 23, 2025 Filed Jun 25, 2025 01:35 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantShare Option (Right to Buy) · Derivative | 185,800 | $0.00 Strike: $31.49 | $0.00 |
DisclosureSEC source: 0000950170-25-089721 · ownership.xml · derivative · entry 1 Cline Darren S · CIK 0001633639 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,800 Underlying: Common Shares · 185,800 shares Expires 2035-06-22 F1 · derivative.exercise_date: Vesting 25% on June 23, 2026, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:43 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantCommon Stock (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.61 | $0.00 |
DisclosureSEC source: 0001746473-25-000127 · wk-form4_1749516208.xml · derivative · entry 1 Cline Darren S · CIK 0001633639 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-06-05 F1 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on October 1, 2025, January 1, 2026, and April 1, 2026, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 5, 2025 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 09:01 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | GrantStock Option (Right to Buy) · Derivative | 36,979 | $0.98 Strike: $0.98 | $36,239.42 |
DisclosureSEC source: 0000950170-25-048899 · ownership.xml · derivative · entry 1 Cline Darren S · CIK 0001633639 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,979 Underlying: Common Stock · 36,979 shares Expires 2035-03-31 F1 · derivative.exercise_date: The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 20:15 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantCommon Stock (Right to Buy) · Derivative | 26,764 | $0.00 Strike: $13.06 | $0.00 |
DisclosureSEC source: 0001746473-24-000103 · wk-form4_1718669734.xml · derivative · entry 1 Cline Darren S · CIK 0001633639 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,764 Underlying: Common Stock · 26,764 shares Expires 2034-06-13 F1 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on the first day of each calendar quarter for three calendar quarters following the June 13th, 2024 grant date and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 13, 2024 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting. Read SEC document |
| March 26, 2024 Filed Mar 28, 2024 16:33 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | GrantCommon Stock | 35,219 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-038105 · ownership.xml · nonDerivative · entry 1 Cline Darren S · CIK 0001633639 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 251,405 F1 · shares: Represents restricted stock units that vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| June 16, 2023 Filed Jun 20, 2023 18:41 UTC | IPI Legacy Liquidation Co IMPL · Entity 15659 | GrantStock Option (right to buy) · Derivative | 13,222 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001209191-23-038606 · doc4.xml · derivative · entry 1 Cline Darren S · CIK 0001633639 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,222 Underlying: Common Stock · 13,222 shares Expires 2033-06-15 F1 · derivative.exercise_date: The option is 100% vested on June 16, 2024. Read SEC document |
| June 07, 2023 Filed Jun 8, 2023 17:09 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $23.09 | $0.00 |
DisclosureSEC source: 0001209191-23-035511 · doc4.xml · derivative · entry 1 Cline Darren S · CIK 0001633639 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2033-06-07 F1 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on the first day of each calendar quarter for three calendar quarters following the June 7th, 2023 grant date and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 7th, 2023 grant date, or (ii) the 2024 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting. Read SEC document |
| April 12, 2023 Filed Apr 14, 2023 16:58 UTC | IPI Legacy Liquidation Co IMPL · Entity 15659 | GrantStock Option (right to buy) · Derivative | 20,013 | $0.00 Strike: $1.42 | $0.00 |
DisclosureSEC source: 0001209191-23-024348 · doc4.xml · derivative · entry 1 Cline Darren S · CIK 0001633639 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,013 Underlying: Common Stock · 20,013 shares Expires 2033-04-11 F1 · derivative.exercise_date: The option vests as to 1/3rd of the total shares on April 12, 2024 and then 1/36th of the total shares vests on each monthly anniversary thereafter, with 100% of the total shares vested and exercisable on April 12, 2026, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| March 24, 2023 Filed Mar 28, 2023 16:41 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | GrantCommon Stock | 139,355 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-021405 · doc4.xml · nonDerivative · entry 1 Cline Darren S · CIK 0001633639 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 216,186 F1 · shares: Represents restricted stock units that vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| March 06, 2023 Filed Mar 8, 2023 16:36 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $31.11 | $0.00 |
DisclosureSEC source: 0001209191-23-017213 · doc4.xml · derivative · entry 1 Cline Darren S · CIK 0001633639 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2033-03-06 F1 · derivative.exercise_date: 1/36th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of March 6, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 16:15 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | GrantCommon Stock | 66,831 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-012914 · form4.xml · nonDerivative · entry 1 Cline Darren S · CIK 0001633639 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,831 F1 · shares: Represents restricted stock units that vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| December 08, 2021 Filed Dec 9, 2021 16:18 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | PurchaseCommon Stock | 10,000 | $9.39 | $93,885.00 |
DisclosureSEC source: 0000899243-21-047525 · doc4.xml · nonDerivative · entry 1 Cline Darren S · CIK 0001633639 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.109 to $9.5561, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein Read SEC document |
| October 07, 2021 Filed Oct 12, 2021 19:47 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | GrantStock Option (Right to buy) · Derivative | 42,191 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001140361-21-034425 · form4.xml · derivative · entry 1 Cline Darren S · CIK 0001633639 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,191 Underlying: Common Stock · 42,191 shares Expires 2031-10-07 F1 · derivative.exercise_date: These stock options vest as to 1/3 of the shares covered by the option on each annual general meeting of the Issuer's stockholders following the October 7, 2021 grant date, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| May 05, 2021 Filed May 7, 2021 16:21 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Disposition to issuerShare Options · Derivative | 75,024 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000899243-21-018670 · doc4.xml · derivative · entry 8 Cline Darren S · CIK 0001633639 · U.S. Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 75,024 shares Expires not disclosed F4 · price: Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023. F4 · derivative.exercise_date: Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023. F5 · derivative.expiration_date: These stock options were granted with automatic vesting on exercisable date. Read SEC document |
| May 05, 2021 Filed May 7, 2021 16:21 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Disposition to issuerShare Options · Derivative | 46,896 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000899243-21-018670 · doc4.xml · derivative · entry 7 Cline Darren S · CIK 0001633639 · U.S. Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 46,896 shares Expires not disclosed F4 · price: Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023. F4 · derivative.exercise_date: Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023. F5 · derivative.expiration_date: These stock options were granted with automatic vesting on exercisable date. Read SEC document |
| May 05, 2021 Filed May 7, 2021 16:21 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Disposition to issuerShare Options · Derivative | 177,180 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000899243-21-018670 · doc4.xml · derivative · entry 6 Cline Darren S · CIK 0001633639 · U.S. Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 177,180 shares Expires not disclosed F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5 · derivative.expiration_date: These stock options were granted with automatic vesting on exercisable date. Read SEC document |
| May 05, 2021 Filed May 7, 2021 16:21 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Disposition to issuerShare Options · Derivative | 106,320 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000899243-21-018670 · doc4.xml · derivative · entry 5 Cline Darren S · CIK 0001633639 · U.S. Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 106,320 shares Expires not disclosed F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5 · derivative.expiration_date: These stock options were granted with automatic vesting on exercisable date. Read SEC document |
| May 05, 2021 Filed May 7, 2021 16:21 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Disposition to issuerShare Options · Derivative | 98,040 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000899243-21-018670 · doc4.xml · derivative · entry 4 Cline Darren S · CIK 0001633639 · U.S. Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 98,040 shares Expires not disclosed F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5 · derivative.expiration_date: These stock options were granted with automatic vesting on exercisable date. Read SEC document |
| May 05, 2021 Filed May 7, 2021 16:21 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Disposition to issuerShare Options · Derivative | 22,068 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000899243-21-018670 · doc4.xml · derivative · entry 3 Cline Darren S · CIK 0001633639 · U.S. Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 22,068 shares Expires not disclosed F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5 · derivative.expiration_date: These stock options were granted with automatic vesting on exercisable date. Read SEC document |
| May 05, 2021 Filed May 7, 2021 16:21 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Disposition to issuerShare Options · Derivative | 54,192 | Not disclosed Strike: $15.30 | Not disclosed |
DisclosureSEC source: 0000899243-21-018670 · doc4.xml · derivative · entry 2 Cline Darren S · CIK 0001633639 · U.S. Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 54,192 shares Expires 2029-05-28 F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. Read SEC document |
| May 05, 2021 Filed May 7, 2021 16:21 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Disposition to issuerOrdinary Shares | 5,556 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-018670 · doc4.xml · nonDerivative · entry 1 Cline Darren S · CIK 0001633639 · U.S. Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement") (continued in footnote 2). F2 · price: At the effective time of the Scheme of Arrangement, Scheme Shareholders (as defined in the Scheme of Arrangement) became entitled to receive for each Scheme Share (as defined in the Scheme of Arrangement) held by them an amount equal to $16.66 2/3 in cash plus 0.010030 ordinary shares, nominal value $0.0001 per share, of Jazz ("Jazz ordinary shares"). The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 21:05 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | GrantShare Options · Derivative | 46,896 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-010022 · doc4.xml · derivative · entry 2 Cline Darren S · CIK 0001633639 · U.S. Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,896 Underlying: Ordinary Shares · 46,896 shares Expires not disclosed F3 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. F6 · security: The share numbers underlying options granted on February 22, 2021 and reported on the reporting person's form 4 filed on February 24, 2021 were amended as of March 2, 2021 and as reported in this form 4. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.41 U.S. Dollars as of February 22, 2021. F4 · derivative.exercise_date: These share options will vest in four equal annual installments beginning on February 22, 2022 and be automatically exercised upon vesting. F5 · derivative.exercise_date: Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc. F4 · derivative.expiration_date: These share options will vest in four equal annual installments beginning on February 22, 2022 and be automatically exercised upon vesting. F5 · derivative.expiration_date: Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 21:05 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | GrantShare Options · Derivative | 75,024 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-010022 · doc4.xml · derivative · entry 1 Cline Darren S · CIK 0001633639 · U.S. Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,024 Underlying: Ordinary Shares · 75,024 shares Expires not disclosed F1 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest and be automatically exercised on February 22, 2024 if certain performance conditions are satisfied. F6 · security: The share numbers underlying options granted on February 22, 2021 and reported on the reporting person's form 4 filed on February 24, 2021 were amended as of March 2, 2021 and as reported in this form 4. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.41 U.S. Dollars as of February 22, 2021. F1 · derivative.exercise_date: Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest and be automatically exercised on February 22, 2024 if certain performance conditions are satisfied. F5 · derivative.exercise_date: Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc. F1 · derivative.expiration_date: Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest and be automatically exercised on February 22, 2024 if certain performance conditions are satisfied. F5 · derivative.expiration_date: Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 18:53 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | GrantShare Options · Derivative | 75,024 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-008099 · doc4.xml · derivative · entry 2 Cline Darren S · CIK 0001633639 · U.S. Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,024 Underlying: Ordinary Shares · 75,024 shares Expires not disclosed F3 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.41 U.S. Dollars as of February 22, 2021. F4 · derivative.exercise_date: These share options will vest in four equal annual installments beginning on February 22, 2022 and be automatically exercised upon vesting. F5 · derivative.exercise_date: Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc. F4 · derivative.expiration_date: These share options will vest in four equal annual installments beginning on February 22, 2022 and be automatically exercised upon vesting. F5 · derivative.expiration_date: Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 18:53 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | GrantShare Options · Derivative | 46,896 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-008099 · doc4.xml · derivative · entry 1 Cline Darren S · CIK 0001633639 · U.S. Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,896 Underlying: Ordinary Shares · 46,896 shares Expires not disclosed F1 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest and be automatically exercised on February 22, 2024 if certain performance conditions are satisfied. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.41 U.S. Dollars as of February 22, 2021. F1 · derivative.exercise_date: Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest and be automatically exercised on February 22, 2024 if certain performance conditions are satisfied. F5 · derivative.exercise_date: Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc. F1 · derivative.expiration_date: Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest and be automatically exercised on February 22, 2024 if certain performance conditions are satisfied. F5 · derivative.expiration_date: Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc. Read SEC document |
| June 10, 2020 Filed Jun 10, 2020 11:15 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | OtherCommon Stock | 35,468 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-071831 · a4.xml · nonDerivative · entry 1 Cline Darren S · CIK 0001633639 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Disposed of in connection with a tender offer made pursuant to an agreement and plan of merger among Issuer, Berlin-Chemie AG, and Mercury Merger Sub, Inc., dated as of May 3, 2020, in exchange for $11.50 per share, net to the holder in cash, plus one contractual contingent value right ("CVR") per share. Each CVR represents the right to receive a payment of $1.00 in cash upon the achievement of a certain milestone relating to the first sale of ELZONRIS in any one of certain countries following a marketing authorization approval by the European Commission. The CVR milestone must be achieved on or prior to December 31, 2021. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 20:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | GrantShare Options · Derivative | 106,320 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-015687 · doc4.xml · derivative · entry 2 Cline Darren S · CIK 0001633639 · U.S. Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,320 Underlying: Ordinary Shares · 106,320 shares Expires not disclosed F2 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. F3 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.26 U.S. Dollars as of June 4, 2020. F4 · derivative.exercise_date: These share options will vest in four equal annual installments beginning on June 4, 2021 and be automatically exercised upon vesting. F4 · derivative.expiration_date: These share options will vest in four equal annual installments beginning on June 4, 2021 and be automatically exercised upon vesting. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 20:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | GrantShare Options · Derivative | 177,180 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-015687 · doc4.xml · derivative · entry 1 Cline Darren S · CIK 0001633639 · U.S. Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,180 Underlying: Ordinary Shares · 177,180 shares Expires not disclosed F1 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest and be automatically exercised on June 4, 2023 if certain performance conditions are satisfied. F3 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.26 U.S. Dollars as of June 4, 2020. F1 · derivative.exercise_date: Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest and be automatically exercised on June 4, 2023 if certain performance conditions are satisfied. F1 · derivative.expiration_date: Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest and be automatically exercised on June 4, 2023 if certain performance conditions are satisfied. Read SEC document |
| May 28, 2020 Filed May 29, 2020 20:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionStock Options · Derivative | 7,356 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-014631 · doc4.xml · derivative · entry 3 Cline Darren S · CIK 0001633639 · U.S. Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 7,356 shares Expires 2020-05-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.23 U.S. Dollars as of May 28, 2020. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. Read SEC document |
| May 28, 2020 Filed May 29, 2020 20:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Tax withholdingOrdinary Shares | 1,800 | $10.54 | $18,972.00 |
DisclosureSEC source: 0000899243-20-014631 · doc4.xml · nonDerivative · entry 2 Cline Darren S · CIK 0001633639 · U.S. Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,556 F3 · shares: Represented by ADS. F4 · price: The price reported is price per ordinary share converted from price per ADS. Read SEC document |
| May 28, 2020 Filed May 29, 2020 20:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionOrdinary Shares | 7,356 | $0.00 | $8.83 |
DisclosureSEC source: 0000899243-20-014631 · doc4.xml · nonDerivative · entry 1 Cline Darren S · CIK 0001633639 · U.S. Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,356 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F2 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.23 U.S. Dollars as of May 28, 2020. F5 · balance_after: Column 5 of Table I of the reporting person's form 4 filed with the SEC on May 30, 2020 includes 29,424 ordinary shares underlying RSU style stock options granted on March 28, 2019 pursuant to the Issuer's Long-Term Incentive Plan, vesting automatically in four equal annual installments beginning on May 28, 2020. These ordinary shares have been excluded from Column 5 of this form 4 and will be reported as each tranche is vested and automatically exercised. The vesting and exercise of the first tranche is reported on this form 4. Read SEC document |
| June 25, 2019 Filed Jun 28, 2019 17:15 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-038307 · a4.xml · nonDerivative · entry 1 Cline Darren S · CIK 0001633639 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,468 F1 · shares: The restricted shares will vest according to the following schedule: 5,000 shares on 6/25/2020, 5,000 shares on 6/25/2021 and 5,000 shares on 6/25/2022. F2 · balance_after: Of the 35,468 shares, 28,645 shares are restricted stock. Read SEC document |
| May 28, 2019 Filed May 30, 2019 20:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | GrantStock Options · Derivative | 98,040 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-015229 · doc4.xml · derivative · entry 3 Cline Darren S · CIK 0001633639 · U.S. Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,040 Underlying: Ordinary Shares · 98,040 shares Expires 2022-05-28 F5 · security: Performance based stock options granted pursuant to the Issuer's Long-Term Incentive Plan. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.27 U.S. Dollars as of May 28, 2019. Read SEC document |
| May 28, 2019 Filed May 30, 2019 20:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | GrantStock Options · Derivative | 54,192 | $0.00 Strike: $15.30 | $0.00 |
DisclosureSEC source: 0000899243-19-015229 · doc4.xml · derivative · entry 2 Cline Darren S · CIK 0001633639 · U.S. Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,192 Underlying: Ordinary Shares · 54,192 shares Expires 2029-05-28 F3 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. The reported options are options to purchase American Depositary Shares of the Issuer ("ADS"). Each ADS represents twelve ordinary shares of the Issuer. F4 · derivative.exercise_price: The exercise price reported is price per ordinary share converted from price per ADS ($183.62). Read SEC document |
| May 28, 2019 Filed May 30, 2019 20:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | GrantOrdinary Shares | 29,424 | $0.00 | $38.25 |
DisclosureSEC source: 0000899243-19-015229 · doc4.xml · nonDerivative · entry 1 Cline Darren S · CIK 0001633639 · U.S. Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,424 F1 · kind: Grant of restricted stock units ("RSUs") pursuant to the Issuer's Long-Term Incentive Plan, which will vest automatically in four equal annual installments beginning on May 28, 2020. F2 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.27 U.S. Dollars as of May 28, 2019. Read SEC document |
| November 29, 2018 Filed Nov 30, 2018 18:32 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 7,000 | $62.88 | $440,160.00 |
DisclosureSEC source: 0001203311-18-000097 · edgardoc.xml · nonDerivative · entry 1 Cline Darren S · CIK 0001633639 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,556 F1 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $62.8711 to $62.9508. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F2 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| November 21, 2018 Filed Nov 21, 2018 18:42 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 4,167 | $56.68 | $236,204.31 |
DisclosureSEC source: 0001203311-18-000095 · edgardoc.xml · nonDerivative · entry 1 Cline Darren S · CIK 0001633639 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,556 F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 20:41 UTC | Seagen Inc. SGEN · Entity 13956 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 42,984 | $0.00 Strike: $76.86 | $0.00 |
DisclosureSEC source: 0001203311-18-000073 · edgardoc.xml · derivative · entry 3 Cline Darren S · CIK 0001633639 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,984 Underlying: Common Stock · 42,984 shares Expires 2028-08-30 F4 · derivative.exercise_date: Shares shall vest at a rate of 25% one year from the grant date and monthly thereafter until all shares are fully vested four years from the grant date. Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 20:41 UTC | Seagen Inc. SGEN · Entity 13956 | GrantIncentive Stock Option (right to buy) · Derivative | 1,301 | $0.00 Strike: $76.86 | $0.00 |
DisclosureSEC source: 0001203311-18-000073 · edgardoc.xml · derivative · entry 2 Cline Darren S · CIK 0001633639 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,301 Underlying: Common Stock · 1,301 shares Expires 2028-08-30 F4 · derivative.exercise_date: Shares shall vest at a rate of 25% one year from the grant date and monthly thereafter until all shares are fully vested four years from the grant date. Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 20:41 UTC | Seagen Inc. SGEN · Entity 13956 | GrantCommon Stock | 18,644 | $0.00 | $0.00 |
DisclosureSEC source: 0001203311-18-000073 · edgardoc.xml · nonDerivative · entry 1 Cline Darren S · CIK 0001633639 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,723 F1 · security: These shares represent restricted stock units and will be settled in common stock upon vesting. F2 · date: Shares shall vest at a rate of 25% on each anniversary of the grant date until all shares are fully vested four years from the grant date. F3 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| August 27, 2018 Filed Aug 29, 2018 19:32 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 4,784 | $74.23 | $355,124.93 |
DisclosureSEC source: 0001203311-18-000061 · edgardoc.xml · nonDerivative · entry 1 Cline Darren S · CIK 0001633639 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,079 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| June 21, 2018 Filed Jun 22, 2018 21:30 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | GrantCommon Stock | 20,468 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-041868 · a4.xml · nonDerivative · entry 1 Cline Darren S · CIK 0001633639 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,468 F1 · shares: The restricted shares will vest according to the following schedule: 6,823 shares on 6/21/2019, 6,823 shares on 6/21/2020 and 6,822 shares on 6/21/2021. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 18:31 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $31.37 | $0.00 |
DisclosureSEC source: 0001203311-18-000051 · edgardoc.xml · derivative · entry 14 Cline Darren S · CIK 0001633639 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,583 Underlying: Common Stock · 8,000 shares Expires 2025-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Shares shall vest at a rate of 25% on 2/03/2016 and monthly thereafter until all the shares are fully vested on 2/03/2019. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 18:31 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 926 | $0.00 Strike: $26.10 | $0.00 |
DisclosureSEC source: 0001203311-18-000051 · edgardoc.xml · derivative · entry 13 Cline Darren S · CIK 0001633639 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 926 shares Expires 2022-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Shares vested at a rate of 25% on 8/20/13 and monthly thereafter until all shares were fully vested on 8/20/16. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 18:31 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 892 | $0.00 Strike: $16.41 | $0.00 |
DisclosureSEC source: 0001203311-18-000051 · edgardoc.xml · derivative · entry 12 Cline Darren S · CIK 0001633639 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 892 shares Expires 2020-10-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Shares vested at a rate of 25% on 10/29/11 and monthly thereafter until all the shares were fully vested on 10/29/14. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 18:31 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 268 | $0.00 Strike: $15.46 | $0.00 |
DisclosureSEC source: 0001203311-18-000051 · edgardoc.xml · derivative · entry 11 Cline Darren S · CIK 0001633639 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 268 shares Expires 2021-08-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Shares vested at a rate of 25% on 8/24/12 and monthly thereafter until all the shares were fully vested on 8/24/15. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.